Li Wang
Chongqing Medical University
20 Papers
17 Citations
Li Wang is an academic researcher from Chongqing Medical University. The author has contributed to research in topics: Ghrelin & Angiogenesis. The author has an hindex of 11, co-authored 18 publications.
Chat about Author
Papers
Ghrelin induces cell migration through GHSR1a-mediated PI3K/Akt/eNOS/NO signaling pathway in endothelial progenitor cells.
TL;DR: The findings suggest that ghrelin stimulates EPC directional migration via GHSR1a-mediated PI3K/Akt/eNOS/NO signal pathway, and indicates that gh Relin may be used as a therapeutic strategy to treat ischemic diseases by promoting E PC directional migration.
55
Association between FTO gene polymorphism and cancer risk: evidence from 16,277 cases and 31,153 controls
TL;DR: The meta-analysis indicated that there was no association between FTO rs9939609 polymorphism and the increased risk of cancer, although this polymorphism was marginally associated with pancreatic cancer.
46
Ghrelin inhibits atherosclerotic plaque angiogenesis and promotes plaque stability in a rabbit atherosclerotic model
TL;DR: Ghrelin can inhibit intraplaque angiogenesis and promote plaque stability by down‐regulating VEGF and VEGFR2 expression, inhibiting the plaque content of macrophages, and reducing MCP‐1 expression at an advanced stage of atherosclerosis in rabbits.
35
Octanoylated ghrelin attenuates angiogenesis induced by oxLDL in human coronary artery endothelial cells via the GHSR1a-mediated NF-κB pathway
TL;DR: It is suggested that octanoylated ghrelin attenuates angiogenesis induced by oxLDL in HCAECs via the inhibition of GHSR1a-mediated NF-κB pathway and may promote the stability of vulnerable plaques by inhibiting plaqueAngiogenesis.
21
[Value of patient health questionnaires (PHQ)-9 and PHQ-2 for screening depression disorders in cardiovascular outpatients].
TL;DR: ThePHQ-2 and PHQ-9 are reliable and efficient instruments for screening and especially excluding depression in cardiovascular outpatients, according to the CIDI.
18